Clal Insurance’s Vertex Pharmaceuticals VRTX Stock Holding History

Clal Insurance’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9K	Sell	21 -4,002	-99%	-$1.87M	﹤0.01%	189
2025 Q4	$1.82M	Sell	4,023 -3	-0.1%	-$1.29K	0.01%	102
2025 Q3	$1.58M	Buy	4,026 +1,506	+60%	+$629K	0.01%	97
2025 Q2	$1.12M	Buy	2,520 +2,465	+4,482%	+$1.14M	0.01%	97
2025 Q1	$27K	Buy	55 +45	+450%	+$21K	﹤0.01%	143
2024 Q4	$4K	Buy	+10	New	+$4.63K	﹤0.01%	158
2023 Q1	–	Sell	-165,240	Closed	-$47.7M	–	160
2022 Q4	$47.7M	Sell	165,240 -47,000	-22%	-$14.3M	0.72%	44
2022 Q3	$61.5M	Sell	212,240 -5,000	-2%	-$1.44M	0.84%	37
2022 Q2	$61.2M	Sell	217,240 -47,760	-18%	-$12.8M	0.81%	41
2022 Q1	$69.2M	Sell	265,000 -216,000	-45%	-$51.3M	0.73%	42
2021 Q4	$106M	Buy	481,000 +323,500	+205%	+$62.9M	1.14%	25
2021 Q3	$28.6M	Buy	157,500 +153,000	+3,400%	+$29.9M	0.33%	85
2021 Q2	$907K	Buy	+4,500	New	+$941K	0.01%	154

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance's VRTX Position: Q1 2026 in Review

Clal Insurance reduced its Vertex Pharmaceuticals (VRTX) stake by 99% in Q1 2026, selling an estimated $1.87M and leaving 21 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #189.

Clal Insurance first reported a position in VRTX in Q2 2021 and has held it in 13 quarters since. The position peaked at $106M in Q4 2021. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Clal Insurance held 21 shares of Vertex Pharmaceuticals worth $9K as of Q1 2026.
Clal Insurance sold 4,002 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.87M.
Vertex Pharmaceuticals made up ﹤0.01% of Clal Insurance's portfolio in Q1 2026, its #189 holding.
Clal Insurance first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 13 quarters since.
Clal Insurance's Vertex Pharmaceuticals position peaked at $106M in Q4 2021.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Clal Insurance's 13F filing for Q1 2026, filed 12 May 2026.